Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 26

1.

Current and Potential Uses of Immunocytokines as Cancer Immunotherapy.

Sondel PM, Gillies SD.

Antibodies (Basel). 2012 Jul 4;1(2):149-171.

PMID:
24634778
[PubMed]
Free PMC Article
2.

Immunocytokines: a review of molecules in clinical development for cancer therapy.

List T, Neri D.

Clin Pharmacol. 2013 Aug 20;5:29-45. doi: 10.2147/CPAA.S49231. eCollection 2013.

PMID:
23990735
[PubMed]
Free PMC Article
3.

Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival.

Yang RK, Kalogriopoulos NA, Rakhmilevich AL, Ranheim EA, Seo S, Kim K, Alderson KL, Gan J, Reisfeld RA, Gillies SD, Hank JA, Sondel PM.

Cancer Immunol Immunother. 2013 Aug;62(8):1303-13. doi: 10.1007/s00262-013-1430-x. Epub 2013 May 10.

PMID:
23661160
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors.

Connor JP, Cristea MC, Lewis NL, Lewis LD, Komarnitsky PB, Mattiacci MR, Felder M, Stewart S, Harter J, Henslee-Downey J, Kramer D, Neugebauer R, Stupp R.

BMC Cancer. 2013 Jan 15;13:20. doi: 10.1186/1471-2407-13-20.

PMID:
23320927
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Ganglioside GD2-specific trifunctional surrogate antibody Surek demonstrates therapeutic activity in a mouse melanoma model.

Ruf P, Schäfer B, Eissler N, Mocikat R, Hess J, Plöscher M, Wosch S, Suckstorff I, Zehetmeier C, Lindhofer H.

J Transl Med. 2012 Nov 7;10:219. doi: 10.1186/1479-5876-10-219.

PMID:
23134699
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention.

Yang RK, Kalogriopoulos NA, Rakhmilevich AL, Ranheim EA, Seo S, Kim K, Alderson KL, Gan J, Reisfeld RA, Gillies SD, Hank JA, Sondel PM.

J Immunol. 2012 Sep 1;189(5):2656-64. doi: 10.4049/jimmunol.1200934. Epub 2012 Jul 27.

PMID:
22844125
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Phase II trial of hu14.18-IL2 for patients with metastatic melanoma.

Albertini MR, Hank JA, Gadbaw B, Kostlevy J, Haldeman J, Schalch H, Gan J, Kim K, Eickhoff J, Gillies SD, Sondel PM.

Cancer Immunol Immunother. 2012 Dec;61(12):2261-71. doi: 10.1007/s00262-012-1286-5. Epub 2012 Jun 8.

PMID:
22678096
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Animal models for IgE-meditated cancer immunotherapy.

Daniels TR, Martínez-Maza O, Penichet ML.

Cancer Immunol Immunother. 2012 Sep;61(9):1535-46. doi: 10.1007/s00262-011-1169-1. Epub 2011 Dec 23. Review.

PMID:
22193986
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cells.

Daniels TR, Leuchter RK, Quintero R, Helguera G, Rodríguez JA, Martínez-Maza O, Schultes BC, Nicodemus CF, Penichet ML.

Cancer Immunol Immunother. 2012 Jul;61(7):991-1003. doi: 10.1007/s00262-011-1150-z. Epub 2011 Nov 30.

PMID:
22127364
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Comparison of GD2 binding capture ELISA assays for anti-GD2-antibodies using GD2-coated plates and a GD2-expressing cell-based ELISA.

Soman G, Yang X, Jiang H, Giardina S, Mitra G.

J Immunol Methods. 2011 Oct 28;373(1-2):181-91. doi: 10.1016/j.jim.2011.08.016. Epub 2011 Aug 26.

PMID:
21893062
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma.

Rudman SM, Jameson MB, McKeage MJ, Savage P, Jodrell DI, Harries M, Acton G, Erlandsson F, Spicer JF.

Clin Cancer Res. 2011 Apr 1;17(7):1998-2005. doi: 10.1158/1078-0432.CCR-10-2490. Epub 2011 Mar 29.

PMID:
21447719
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Differential internalization of hu14.18-IL2 immunocytokine by NK and tumor cell: impact on conjugation, cytotoxicity, and targeting.

Buhtoiarov IN, Neal ZC, Gan J, Buhtoiarova TN, Patankar MS, Gubbels JA, Hank JA, Yamane B, Rakhmilevich AL, Reisfeld RA, Gillies SD, Sondel PM.

J Leukoc Biol. 2011 Apr;89(4):625-38. doi: 10.1189/jlb.0710422. Epub 2011 Jan 19.

PMID:
21248148
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study.

Shusterman S, London WB, Gillies SD, Hank JA, Voss SD, Seeger RC, Reynolds CP, Kimball J, Albertini MR, Wagner B, Gan J, Eickhoff J, DeSantes KB, Cohn SL, Hecht T, Gadbaw B, Reisfeld RA, Maris JM, Sondel PM.

J Clin Oncol. 2010 Nov 20;28(33):4969-75. doi: 10.1200/JCO.2009.27.8861. Epub 2010 Oct 4.

PMID:
20921469
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Anti-GD2 antibody therapy for GD2-expressing tumors.

Navid F, Santana VM, Barfield RC.

Curr Cancer Drug Targets. 2010 Mar;10(2):200-9. Review.

PMID:
20201786
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis.

Schwager K, Kaspar M, Bootz F, Marcolongo R, Paresce E, Neri D, Trachsel E.

Arthritis Res Ther. 2009;11(5):R142. doi: 10.1186/ar2814. Epub 2009 Sep 25.

PMID:
19781067
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Immunogenicity of the hu14.18-IL2 immunocytokine molecule in adults with melanoma and children with neuroblastoma.

Hank JA, Gan J, Ryu H, Ostendorf A, Stauder MC, Sternberg A, Albertini M, Lo KM, Gillies SD, Eickhoff J, Sondel PM.

Clin Cancer Res. 2009 Sep 15;15(18):5923-30. doi: 10.1158/1078-0432.CCR-08-2963. Epub 2009 Sep 8.

PMID:
19737959
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma.

Ribas A, Kirkwood JM, Atkins MB, Whiteside TL, Gooding W, Kovar A, Gillies SD, Kashala O, Morse MA.

J Transl Med. 2009 Jul 29;7:68. doi: 10.1186/1479-5876-7-68.

PMID:
19640287
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma.

Yamane BH, Hank JA, Albertini MR, Sondel PM.

Expert Opin Investig Drugs. 2009 Jul;18(7):991-1000. doi: 10.1517/13543780903048911. Review.

PMID:
19548853
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Immune therapies for neuroblastoma.

Navid F, Armstrong M, Barfield RC.

Cancer Biol Ther. 2009 May;8(10):874-82. Epub 2009 May 9. Review.

PMID:
19342881
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group.

Gilman AL, Ozkaynak MF, Matthay KK, Krailo M, Yu AL, Gan J, Sternberg A, Hank JA, Seeger R, Reaman GH, Sondel PM.

J Clin Oncol. 2009 Jan 1;27(1):85-91. doi: 10.1200/JCO.2006.10.3564. Epub 2008 Dec 1.

PMID:
19047298
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk